Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1, 2 See details »
The financial information indicates fluctuations in both net cash flows from operating activities and free cash flow to the firm (FCFF) over the five-year period. While both metrics demonstrate overall stability, there are discernible shifts in their trajectories.
- Net Cash Flows from Operating Activities
- Net cash flows from operating activities experienced a decrease from US$23,410 million in 2021 to US$21,194 million in 2022. A subsequent recovery was observed in 2023, reaching US$22,791 million, followed by further increases to US$24,266 million in 2024 and US$24,530 million in 2025. This suggests a strengthening of core operational cash generation in the later years of the observed period.
- Free Cash Flow to the Firm (FCFF)
- FCFF mirrored the trend in operating cash flows, declining from US$20,666 million in 2021 to US$17,996 million in 2022. A recovery began in 2023, with FCFF reaching US$19,873 million. Continued growth was evident in 2024, with FCFF increasing to US$21,520 million, and remained relatively stable in 2025 at US$21,325 million. The FCFF trend closely follows the operating cash flow trend, indicating a strong correlation between the two.
The period between 2021 and 2022 shows a concurrent decrease in both operating cash flows and FCFF. The subsequent years demonstrate a consistent upward trend in both metrics, suggesting improved financial performance and cash generation capabilities. The stabilization of FCFF in 2025, while still at a healthy level, warrants monitoring to determine if this represents a plateau or a temporary pause in growth.
- Relationship between Operating Cash Flow and FCFF
- The difference between net cash flows from operating activities and FCFF remains relatively consistent across the observed period. This suggests that the factors impacting FCFF, beyond core operations, are also relatively stable. Further investigation into the components of this difference would be necessary to provide a more detailed understanding.
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2 2025 Calculation
Cash paid during the year for interest, net of amount capitalized, tax = Cash paid during the year for interest, net of amount capitalized × EITR
= × =
3 2025 Calculation
Interest expense capitalized, tax = Interest expense capitalized × EITR
= × =
The period under review demonstrates fluctuations in both interest payments, net of tax, and the effective income tax rate. A notable increase in net interest paid is observed between 2021 and 2023, followed by relative stabilization in subsequent years. The effective income tax rate exhibits volatility, impacting the after-tax cost of debt.
- Net Interest Paid
- Cash paid for interest, net of tax, decreased from US$863 million in 2021 to US$771 million in 2022, representing a decline of approximately 10.7%. A substantial increase is then seen in 2023, rising to US$1,563 million, and continuing to US$1,611 million in 2024. The final year reviewed, 2025, shows a slight decrease to US$1,533 million. This suggests a period of increased borrowing or higher interest rates between 2022 and 2024, with a modest reduction in 2025.
- Interest Expense Capitalized, Net of Tax
- The amount of interest expense capitalized, net of tax, has generally trended upward. Starting at US$45 million in 2021, it increased to US$40 million in 2022, then rose steadily to US$62 million in 2023, US$67 million in 2024, and reaching US$94 million in 2025. This indicates a growing proportion of interest costs being deferred as part of asset acquisition or construction costs.
- Effective Income Tax Rate (EITR)
- The effective income tax rate experienced significant variation. It began at 8.30% in 2021, increased substantially to 17.40% in 2022, then decreased to 11.50% in 2023. A further increase to 15.70% occurred in 2024, followed by a rise to 17.70% in 2025. These fluctuations in the EITR would directly influence the after-tax amount of interest expense, contributing to the observed changes in net interest paid.
The combined effect of these factors suggests that while the underlying interest obligations have increased, the actual cash outflow is also influenced by the company’s tax position. The increasing capitalization of interest expense suggests a growing investment in long-term assets.
Enterprise Value to FCFF Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | |
| Free cash flow to the firm (FCFF) | |
| Valuation Ratio | |
| EV/FCFF | |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| AbbVie Inc. | |
| Amgen Inc. | |
| Bristol-Myers Squibb Co. | |
| Danaher Corp. | |
| Eli Lilly & Co. | |
| Gilead Sciences Inc. | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| Thermo Fisher Scientific Inc. | |
| Vertex Pharmaceuticals Inc. | |
| EV/FCFF, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | |
| EV/FCFF, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2025-12-28).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | ||||||
| Free cash flow to the firm (FCFF)2 | ||||||
| Valuation Ratio | ||||||
| EV/FCFF3 | ||||||
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| EV/FCFF, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| EV/FCFF, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio exhibits fluctuations over the observed period. Initially, the ratio increased, followed by a decrease, and then a substantial rise in the most recent year.
- Enterprise Value (EV)
- Enterprise Value decreased from US$439,101 million in 2021 to US$428,242 million in 2022, representing a decline of approximately 2.5%. A further decrease was noted in 2023, falling to US$383,498 million. A modest increase occurred in 2024, reaching US$390,710 million, before a significant jump to US$608,279 million in 2025.
- Free Cash Flow to the Firm (FCFF)
- Free Cash Flow to the Firm experienced a decrease from US$20,666 million in 2021 to US$17,996 million in 2022, a reduction of roughly 12.7%. FCFF then recovered to US$19,873 million in 2023 and continued to rise to US$21,520 million in 2024. In 2025, FCFF remained relatively stable at US$21,325 million, showing a slight decrease from the prior year.
- EV/FCFF Ratio
- The EV/FCFF ratio increased from 21.25 in 2021 to 23.80 in 2022, indicating a less favorable valuation based on free cash flow. The ratio subsequently decreased to 19.30 in 2023 and further to 18.16 in 2024, suggesting an improving valuation. However, the ratio experienced a substantial increase to 28.52 in 2025, driven primarily by the significant rise in Enterprise Value, indicating a considerably higher valuation relative to free cash flow generation in that year.
The observed trend suggests that while the firm’s ability to generate free cash flow has been relatively stable, changes in the market’s assessment of the firm’s overall value, as reflected in Enterprise Value, have had a more pronounced impact on the EV/FCFF ratio. The substantial increase in the ratio in 2025 warrants further investigation to understand the underlying drivers of the increased Enterprise Value.